Adicet Bio, Inc. (ACET)


-0.32 (-5.64%)
Symbol ACET
Price $5.35
Beta 1.913
Volume Avg. 0.46M
Market Cap 229.823M
Shares () -
52 Week Range 4.61-21.87
1y Target Est -
DCF Unlevered ACET DCF ->
DCF Levered ACET LDCF ->
ROE -28.89% Sell
ROA -26.52% Sell
Operating Margin -
Debt / Equity 13.12% Neutral
P/E -1.95 Sell
P/B 0.75 Buy


Consensus EPS

Upgrades & Downgrades

Latest ACET news

Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA
NASDAQ Global Market

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.